A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(22 sites)

United States

Clinical Trial Site, Los Angeles, California

Rush University Medical Center, Chicago, Illinois

Clinical Trial Site, Baltimore, Maryland

Clinical Trial Site, Kansas City, Missouri

Rare Disease Research, Hillsborough, North Carolina